Maja Maraldo

Improving and optimising treatment and care for breast and pediatric cancer patients

[Maja Maraldo @MajaMaraldo]

Waiting for our 2nd day of the ESTRO online workshop on #breastcancer with amazing co-teachers Philip Poortmans, Orit Kaidar-Person, Sandra Hol, Senem Alanyali and Andrea Collavini from @ESTRO_RT

[Tour de France™ @LeTour]

🔁 RT if you think 🇩🇰 @Mads__Pedersen is the Super-combative of the #TDF2023!

🔁 RT si vous pensez que 🇩🇰 @Mads__Pedersen est le Super-combatif du #TDF2023 !

[Maryam Garousi @Dr_m_garousi]

Integration of CDK4/6inhibitors with radiation therapy?
In the adjuvant setting should be avoided because of limited data!
In the metastatic setting the available data encouraging the combination might be safe
@OncoAlert
#florencebreast23

[Marta Perachino @MartaPerachino]

➡️Combining RT with anti-Her2 agents
⛔️main concerns: ❤️‍🩹toxicity and pneumonitis (for eBC)
EARLY-SETTING
✅ Lapatinib, Trast, Pert
⚠️no data for Neratinib
MBC
✅ Lapatibib, Trast, Pert even for intracranial RT
@OncoAlert

[Gustavo @gusviani]

🎙PBI ✖️WBI for early-stage #breastcancer: @JNCI_Now
📌Metanalysis:17,234 👥➡️14 RCTs & 6 observational
- 🥇endpoints: IBR,cosmetics & AEs
📊Findings:
👉5y IBR: PBI = WBI (RR 1.34, 95% CI 0.83—2.18)
👉10y IBR: PBI = WBI (RR 1.29, 95% CI 0.87—1.91)
👉Cosmesis:Insufficient evidence ⚠️
👉Acute AEs: ⬇️PBI✖️WBI
👉 Late AEs: NO sig #
👉IORT:⬆️IBR✖️WBI at 5, 10, >10 y⚠️
#radonc #TreatmentOption

[Icro Meattini @Icro_Meattini]

Congratulations @marianneaznar for this team effort!

Just published the @ESTRO_RT -ACROP guideline: recommendations on implementation of breath-hold techniques in #radiotherapy

@OncoAlert #OncoAlert #radonc #medphys #rtt

https://t.co/gMqVa5IKE4

[Journal of Clinical Oncology @JCO_ASCO]

Check out what’s popular this week in #JCO:

Impact of F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced #BreastCancer ➡️ https://t.co/Bh5dSu3e80 #BCSM #oncorad

[Icro Meattini @Icro_Meattini]

Dose-escalated SIB #radiotherapy in early #breastcancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, randomised controlled trial
Another amazing job led by Charlotte Coles and the UK breast network @ESTRO_RT @OncoAlert #radonc #OncoAlert
https://t.co/W8Tqvb4cx8

[Agon Olloni @AgonOlloni]

New article on coronary calcium score and its impact on survival for lung cancer patients. National collaboration thanks to @DCCC_RT. Tumor and patient-related factors are the most important.
@RadiotherapyOn1 @onko_ouh https://t.co/VYICGyp15V

[Maja Maraldo @MajaMaraldo]

End of another great ⁦@ESTRO_RT⁩ #ESTRO school course on ‘IMRT/VMAT and other highly conformal techniques in clinical practice’ in Turin, IT! Thanks delegates and faculty

[Timothée Olivier, MD @Timothee_MD]

Looks like a great study and findings.
Why are the SONIA trial results not published in the NEJM today ?

I wonder...

[Maja Maraldo @MajaMaraldo]

Amazing response rates in our ‘what did we learn today’-quiz, 3rd day of #ESTRO_school ‘IMRT/VMAT and other highly conformal techniques in practice’

[Enrique Soto @EnriqueSoto8]

The NATALEE trial was presented today. A deep critical evaluation of its results is warranted. It would be great if presentations steered clear of hype phrases like "highly significant" or "safe and well tolerable" #ASCO23 #bcsm

[Maja Maraldo @MajaMaraldo]

Thanks to @unito for a great 1st day of @ESTRO_RT course on ‘IMRT/VMAT and other conformal techniques in practice’

[Jame Abraham, MD, FACP @jamecancerdoc]

Excellent article with practical tips by @hoperugo Real-World Perspectives for Pneumonitis/Interstitial Lung Disease Associated With Trastuzumab Deruxtecan Use in Her-2 + #MetastaticBreastCancer https://t.co/oL2jSKYSFr @ASCO @JCOOP_ASCO @OncoAlert

[OncoAlert @OncoAlert]

Dear Colleagues🌐A warm invite to join us in Florence June 16-17, 2023 for #FlorenceBreast23
Registration is NOW Open
https://t.co/xEgHrcdFhP

Introducing Our #SoMe Ambassador
@FrancicaPaola 🇨🇭of University of Bern

on her Proposal "Using the power of genome-wide genetic🧬screens for the identification of predictive biomarkers of radiotherapy☢️response as well as new treatment strategies to enhance tumors' sensitivity to irradiation." More videos coming soon from
@ChelainG
@MartaPerachino
@FatjonaKrajaMD
@Dr_m_garousi
@acampsmalea

This Meeting is brought to you by FRO and endoresed by @ESTRO_RT @AiroBreast @AIOMtweet and is in partnership w/ @OncoAlert
@Icro_Meattini
@matteolambe
@E_de_Azambuja
@hoperugo
@curijoey
@AnnaKirby17
@TanjaSpanic
@JavierCortesMD
@CarlottaB
@MarcBa12
@barlesi
@FAndreMD

[Paolo Tarantino @PTarantinoMD]

With #ASCO23-week officially here, it is time for a #top10 list of breast abstracts! Several potentially practice-changing trials to be presented during the congress. Take a look, share if you found it useful and feel free to recommend additional impactful abstracts to add! #bcsm

[JAMA Oncology @JAMAOnc]

The monarchE trial of adjuvant abemaciclib endocrine therapy demonstrated benefit for patients with HR /HER2-, node-positive, high risk early #BreastCancer who received neoadjuvant chemotherapy before trial enrolment. https://t.co/XqAmgwop4w #BCSM

[ESTRO @ESTRO_RT]

#ESTROschool The IMRT faculty and ESTRO wants to thank the Institute of Oncology Ljubljana (AT), Primoz Strojan and the entire team for offering a highly substantial course, with insightful lectures and on-site demonstrations!

[The Lancet Haematology @TheLancetHaem]

Our June issue is out!🎉

Featuring trials in multiple myeloma, AML, mycosis fungoides, and myelofibrosis, a Viewpoint making the case for the term "classical #hematology", a Review on cardioprotection for lymphoma patients, and more! #mmsm #leusm #lymsm https://t.co/EyrqUdHpyd